CJC-1295 + Ipamorelin Blend
Ipamorelin is a selective growth hormone secretagogue studied for its high receptor specificity in ghrelin/GHS-R pathway research. Unlike broader-acting secretagogues, it demonstrates minimal cross-reactivity with cortisol and prolactin pathways, making it a clean reference compound for GH-axis studies. For research purposes only.
Weekdays before 2PM EST
With Every Batch
Tested in USA
Buy now, pay later with Afterpay, Klarna & Affirm
Research Overview
CJC-1295 + Ipamorelin Blend combines a GHRH analog (CJC-1295 no DAC/Mod GRF 1-29) with a selective growth hormone secretagogue (Ipamorelin). This combination is widely researched for its synergistic effect on growth hormone release — CJC-1295 amplifies the GH pulse amplitude while Ipamorelin increases GH pulse frequency, without significantly raising cortisol or prolactin.
Mechanism of Action
CJC-1295 (Mod GRF 1-29) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. Ipamorelin binds to the ghrelin/GHS receptor (GHS-R1a) on the same cells, providing an independent stimulatory signal. When combined, these two pathways produce a greater GH response than either peptide alone, while Ipamorelin's selectivity avoids cortisol and prolactin elevation seen with other secretagogues like GHRP-6.
Experimental Applications
Used in GH pulse optimization studies, age-related GH decline research, body composition and metabolic studies in animal models, sleep and recovery investigations, and comparative pharmacology studies against single-peptide GH secretagogue protocols.
Compound Specifications
| Compound Type | Peptide Blend (GHRH + GHSS) |
| Purity | ≥ 99% |
| Appearance | White lyophilized powder |
| Storage | -20°C long-term; 2-8°C short-term |
| Testing Methods | HPLC, Mass Spectrometry |
| Packaging | Sealed sterile vial |
Certificate of Analysis
Lab Testing Notes
Blend ratio and individual peptide purity verified via independent HPLC and Mass Spectrometry testing. Each component tested separately for identity confirmation. Full COA available on this product page.
Mechanism of Action
CJC-1295 (Mod GRF 1-29) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. Ipamorelin binds to the ghrelin/GHS receptor (GHS-R1a) on the same cells, providing an independent stimulatory signal. When combined, these two pathways produce a greater GH response than either peptide alone, while Ipamorelin's selectivity avoids cortisol and prolactin elevation seen with other secretagogues like GHRP-6.
Experimental Applications
Used in GH pulse optimization studies, age-related GH decline research, body composition and metabolic studies in animal models, sleep and recovery investigations, and comparative pharmacology studies against single-peptide GH secretagogue protocols.
Reconstitution Guidelines
Reconstitute with bacteriostatic water. Inject slowly along vial wall. Swirl gently — do not shake. Recommended: 1–2 mL per vial. Store at 2–8°C. Use within 30 days of reconstitution.
Related Peptides
Premium research peptides, lab-tested for purity
